- Home
- MTNB vs PTIX Comparison
MTNB vs PTIX Comparison
Compare MTNB & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- PTIX
- Stock Information
- Founded
- MTNB 2013
- PTIX 1994
- Country
- MTNB United States
- PTIX United States
- Employees
- MTNB N/A
- PTIX N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- PTIX Health Care
- Exchange
- MTNB Nasdaq
- PTIX Nasdaq
- Market Cap
- MTNB 3.0M
- PTIX 3.2M
- IPO Year
- MTNB N/A
- PTIX 2016
- Fundamental
- Price
- MTNB $0.58
- PTIX $0.37
- Analyst Decision
- MTNB Hold
- PTIX
- Analyst Count
- MTNB 1
- PTIX 0
- Target Price
- MTNB N/A
- PTIX N/A
- AVG Volume (30 Days)
- MTNB 1.0M
- PTIX 331.1K
- Earning Date
- MTNB 03-26-2025
- PTIX 03-31-2025
- Dividend Yield
- MTNB N/A
- PTIX N/A
- EPS Growth
- MTNB N/A
- PTIX N/A
- EPS
- MTNB N/A
- PTIX N/A
- Revenue
- MTNB N/A
- PTIX N/A
- Revenue This Year
- MTNB N/A
- PTIX N/A
- Revenue Next Year
- MTNB N/A
- PTIX N/A
- P/E Ratio
- MTNB N/A
- PTIX N/A
- Revenue Growth
- MTNB N/A
- PTIX N/A
- 52 Week Low
- MTNB $0.48
- PTIX $0.35
- 52 Week High
- MTNB $21.50
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- MTNB 43.31
- PTIX 38.67
- Support Level
- MTNB $0.53
- PTIX $0.36
- Resistance Level
- MTNB $0.70
- PTIX $0.44
- Average True Range (ATR)
- MTNB 0.06
- PTIX 0.06
- MACD
- MTNB 0.00
- PTIX -0.01
- Stochastic Oscillator
- MTNB 13.92
- PTIX 6.69
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.